Trials / Completed
CompletedNCT03878082
Propacetamol to Reduce Post Cesarean Section Uterine Contraction Pain
Perioperative Regular Usage of Propacetamol to Reduce Post Cesarean Section Uterine Contraction Pain and Opioid Consumption
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Mackay Memorial Hospital · Academic / Other
- Sex
- Female
- Age
- 20 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
To evaluate that perioperative regular usage of propacetamol to reduce post cesarean section uterine contraction pain and opioid consumption
Detailed description
The most common method of pain control after cesarean section is intravenous patient-control analgesia (IVPCA) with morphine. Multimodal analgesia could improve the quality of perioperative pain control and reduceside effects of opioids. Previous researches marked that perioperative pain after cesarean section includes somatic wound pain and visceral uterine contraction pain. According to Academy of Breastfeeding Medicine, propacetamol is a safe pain-killer for an expectant mother and almost free from breast milk after intravenous injection. This study is a prospective double-blind randomized-controlled trial to evaluate that propacetamol could reduce visceral uterine contraction pain after cesarean section. Post cesarean section women will divide into three groups: 1. pain control with IVPCA for 2 days 2. pain control with IVPCA and propacetamol 1g every 6 hours for 2 days 3. pain control with IVPCA and propacetamol 2g every 6 hours for 2 days
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Propacetamol 1g | pain control with IVPCA and propacetamol 1g every 6 hours for 2 days |
| DRUG | Propacetamol 2g | pain control with IVPCA and propacetamol 2g every 6 hours for 2 days |
| DRUG | IVPCA | pain control with IVPCA |
Timeline
- Start date
- 2019-08-12
- Primary completion
- 2022-12-30
- Completion
- 2022-12-31
- First posted
- 2019-03-18
- Last updated
- 2023-03-15
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT03878082. Inclusion in this directory is not an endorsement.